Disease · MONDO_0006608
Trials18
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 18 of 18
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00703846 | STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% | Phase 4 | 498 | 2012-02-23 | Dermatitis, Seborrheic | KETOCONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04973228 | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) | Phase 3 | 457 | 2024-03-12 | Seborrheic Dermatitis | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT04445987 | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Phase 2 | 408 | 2024-06-11 | Seborrheic Dermatitis | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT00862654 | Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis | Phase 3 | 326 | 2011-08-12 | Scalp Seborrheic Dermatitis | CLOBETASOL PROPIONATE, KETOCONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04091646 | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Phase 2 | 226 | 2023-07-03 | Seborrheic Dermatitis | ROFLUMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT00403559 | A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis | Phase 2 | 113 | 2022-03-14 | Seborrheic Dermatitis | KETOCONAZOLE, PIMECROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT03830177 | Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult | Phase 1/2 | 77 | 2025-02-24 | Dermatitis, Seborrheic, Dry Skin; Eczema | HONEY | Its record names the disease | ClinicalTrials.gov |
| NCT05787860 | Ruxolitinib in Seborrheic Dermatitis | Phase 2 | 45 | 2025-05-06 | Seborrheic Dermatitis | RUXOLITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01203189 | Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo | Not applicable | 23 | 2017-11-06 | Seborrheic Dermatitis | KETOCONAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01011621 | Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis | Phase 3 | 170 | Dermatitis, Atopic, Dermatitis, Contact, Dermatitis, Seborrheic, Psoriasis | BETAMETHASONE VALERATE, PREDNISOLONE ACETATE | Its record names the disease | ClinicalTrials.gov | |
| NCT02004860 | Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis | Phase 3 | 120 | Severe Seborrheic Dermatitis | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT02749383 | A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis | Phase 2 | 75 | Seborrheic Dermatitis | PAC-14028 | Its record names the disease | ClinicalTrials.gov | |
| NCT00408330 | A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face | Phase 2 | 48 | Seborrheic Dermatitis on the Face | AZELAIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT00767546 | Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients | Phase 1 | 40 | Parkinson Disease, Parkinsonism, Seborrheic Dermatitis | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov | |
| NCT03688971 | Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis | Phase 2 | 36 | Seborrheic Dermatitis | OMIGANAN | Its record names the disease | ClinicalTrials.gov | |
| NCT06013371 | PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea | Phase 2 | 32 | Seborrheic Dermatitis, Papulopustular Rosacea | IDREBORMILAST | Its record names the disease | ClinicalTrials.gov | |
| NCT01736670 | An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses | Not applicable | 30 | Acute Steroid Responsive Dermatoses, Chronic Steroid Responsive Dermatoses | TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03114111 | Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis | Early phase 1 | 12 | Seborrheic Dermatitis | AMINOLEVULINIC ACID | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006608/trials